ReviewACS applied materials & interfaces2026
Stimuli-Responsive Zirconium-Based Metal-Organic Frameworks for Targeted Cancer Drug Delivery.
Review in ACS applied materials & interfaces, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metal-organic frameworks (MOFs) have emerged as versatile nanoplatforms for cancer drug delivery owing to their exceptionally high porosity, tunable pore architecture, modular composition, and flexible surface chemistry. In particular, zirconium-based MOFs (Zr-MOFs) have gained considerable attention owing to their good chemical stability, favorable biocompatibility, and ease of functional modification through coordination interactions. These attributes enable precise control over drug loading, surface functionalization, and stimulus-triggered release behavior. Recent advances in stimuli-responsive Zr-MOFs have enabled precise and tumor-selective drug delivery by utilizing intrinsic features of the tumor microenvironment (TME), such as acidic pH, redox gradients, elevated ATP levels, abnormal enzyme activity, and ionic variations, along with externally applied triggers, including light, heat, and ultrasound. This review presents a comprehensive and systematic overview of endogenous, exogenous, and multistimuli-responsive Zr-MOF nanoplatforms for targeted cancer drug delivery. We discuss key Zr-MOF structural families, design strategies for stimulus-responsive behavior, and the underlying structure-stimulus-function relationships that govern therapeutic performance. Representative examples are critically analyzed with respect to drug loading capacity, release mechanisms, targeting strategies, and in vitro and in vivo anticancer efficacy. Additionally, current limitations, including biosafety concerns, degradation behavior, tumor heterogeneity, and barriers to clinical translation, are addressed. Finally, future perspectives are outlined to support the rational development of next-generation Zr-MOF-based nanomedicines with improved precision, controllability, and clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.